ES
Evan Seigerman BMO Capital Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $530 |
34%
upside
| Outperform |
5 Aug ‘25
1 month ago |
|
2
Incyte
INCY
$16.9B
| $86.64 | $60 |
31%
downside
| Underperform |
30 Jul ‘25
1 month ago |
|
3
Disc Medicine
IRON
$2.11B
| $60.76 | $120 |
98%
upside
| Outperform |
12 May ‘25
3 months ago |
|
4
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $115 |
20%
downside
| Market Perform |
6 May ‘25
4 months ago |
|
5
Gilead Sciences
GILD
$143B
| $115.05 | $120 |
4%
upside
| Outperform |
17 Apr ‘25
4 months ago |
|
6
Biogen
BIIB
$20.6B
| $140.67 | $139 |
1%
downside
| Market Perform |
13 Feb ‘25
6 months ago |
|
7
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $61 |
29%
upside
| Market Perform |
12 Nov ‘24
10 months ago |
|
8
Eli Lilly
LLY
$652B
| $727.21 | $1,101 |
51%
upside
| Outperform |
9 Aug ‘24
1 year ago |
|
9
Structure Therapeutics
GPCR
$1.27B
| $22.08 | $40 |
81%
upside
| Outperform |
28 Feb ‘23
2 years ago |
|
10
Replimune Group
REPL
$494M
| $6.33 | $40 |
532%
upside
| Outperform |
14 Oct ‘22
2 years ago |
|
11
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $788 |
37%
upside
| Outperform |
4 Aug ‘22
3 years ago |
|
12
Nuvation Bio
NUVB
$1.33B
| $3.90 | $2.50 |
36%
downside
| Market Perform |
2 Aug ‘22
3 years ago |
|
13
Amgen
AMGN
$153B
| $283.64 | $243 |
14%
downside
| Market Perform |
28 Apr ‘22
3 years ago |
|
14
Candel Therapeutics
CADL
$274M
| $5 | $12 |
140%
upside
| Outperform |
31 Mar ‘22
3 years ago |
|
15
Pfizer
PFE
$141B
| $24.88 | $60 |
141%
upside
| Outperform |
19 Nov ‘21
3 years ago |
|
|
IMA
16
ImageneBio, Inc. Common Stock
IMA
$89M
| $7.96 | $324 |
3,970%
upside
| Outperform |
13 Aug ‘21
4 years ago |
|
|
17
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $760 |
33%
upside
| Outperform |
23 Feb ‘21
4 years ago |
|
|
18
Gilead Sciences
GILD
$143B
| $115.05 | $66 |
43%
downside
| Neutral |
5 Feb ‘21
4 years ago |
|
|
19
Biogen
BIIB
$20.6B
| $140.67 | $338 |
140%
upside
| Outperform |
4 Feb ‘21
4 years ago |
|
|
20
Amgen
AMGN
$153B
| $283.64 | $265 |
7%
downside
| Outperform |
3 Feb ‘21
4 years ago |
|
|
21
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $280 |
29%
downside
| Outperform |
2 Feb ‘21
4 years ago |
|
|
22
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $90 |
38%
downside
| Neutral |
10 Nov ‘20
4 years ago |
|
23
Talphera
TLPH
$11.3M
| $0.5492 | $16.80 |
2,959%
upside
| Underperform |
13 Aug ‘20
5 years ago |
|
|
24
Incyte
INCY
$16.9B
| $86.64 | $97 |
12%
upside
| Neutral |
6 Aug ‘20
5 years ago |
|
25
MacroGenics
MGNX
$126M
| $2 | $30 |
1,400%
upside
| Outperform |
12 May ‘20
5 years ago |
|